AI-Driven Diabetic Retinopathy Screening Market Overview:
The AI-Driven Diabetic Retinopathy Screening Market was valued at US$ 0.4 Billion in 2024 and is anticipated to reach US$ 2.22 Billion by 2033, at a CAGR of 0.21 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the AI-Driven Diabetic Retinopathy Screening Market.

This report delivers a comprehensive overview of the AI-Driven Diabetic Retinopathy Screening Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding AI-Driven Diabetic Retinopathy Screening Market. The AI-Driven Diabetic Retinopathy Screening Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

AI-Driven Diabetic Retinopathy Screening Market Scope:
By Component
• Software
• Hardware
• Services

By Screening Modality
• Automated Screening
• Semi-Automated Screening
• Tele-ophthalmology-Integrated Screening

By Disease Severity Classification
• No Apparent Diabetic Retinopathy
• Mild Non-Proliferative Diabetic Retinopathy (NPDR)
• Moderate Non-Proliferative Diabetic Retinopathy (NPDR)
• Severe Non-Proliferative Diabetic Retinopathy (NPDR)
• Proliferative Diabetic Retinopathy (PDR)
• Diabetic Macular Edema (DME) Detection

By Imaging Technology
• Fundus Photography
• Optical Coherence Tomography (OCT)
• Ultra-Widefield Retinal Imaging
• Fluorescein Angiography (AI-assisted analysis)
• Multimodal Retinal Imaging (Fundus + OCT + Clinical Data)

By End User
• Hospitals
• Clinics
• Ambulatory Surgical Centers (ASCs)
• Primary Care Settings
• Others

By Deployment Mode
• On-Premises
• Cloud-Based
• Hybrid Deployment

By Clinical Workflow Integration
• Standalone AI Screening Tools

By AI Technology
• Deep Learning (CNN-based models)
• Machine Learning (Traditional classifiers)
• Computer Vision Algorithms
• Ensemble AI Models
• Explainable AI (XAI) Systems

By Application
• Mass Population Screening
• Early Disease Detection & Risk Assessment
• Disease Progression Monitoring
• Treatment Response Monitoring
• Referral Decision Support
• Clinical Research & Real-World Evidence Generation

By Patient Demographics
• Adult Diabetic Population
• Pediatric & Adolescent Diabetics
• Geriatric Population
• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes (screening use cases)

By Regulatory & Validation Status
• Research-Use-Only (RUO) Systems
• Clinically Validated AI Tools
• Regulatory-Approved Systems (FDA, CE, CDSCO)
• Reimbursement-Eligible AI Solutions

Key Players
• Digital Diagnostics lnc.
• Topcon Healthcare
• Eyenuk, Inc.
• AEYE Health
• IRIS (Intelligent Retinal Imaging Systems).
• Optomed Plc
• Forus Health (3nethra)
• iCare

Major Highlights
This report delivers a comprehensive overview of the AI-Driven Diabetic Retinopathy Screening Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding AI-Driven Diabetic Retinopathy Screening Market. The AI-Driven Diabetic Retinopathy Screening Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification
✓ Increase Your Customer Base by 3X using our Partner Identification tool
✓ Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
✓ Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
✓ Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

1. Definition and Overview
1.1. Study Objectives
1.2. Market Definition
1.3. Market Scope
1.4. Stakeholder Analysis
1.5. Currency Considered
1.6. Study Period
2. Executive Summary
2.1. Key Takeaways
2.2. Top To Bottom Analysis
2.3. Market Share Analysis
2.4. Data Points from Key Primary Interviews
2.5. Data Points from Key Secondary Databases
2.6. Market Snapshot
2.7. Geographical Snapshot
3. Dynamics
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Diabetes & Diabetic Retinopathy
3.1.1.2. Advancements in AI Technology
3.1.1.3. Focus on Accessibility & Point-of-Care Screening
3.1.2. Restraints
3.1.2.1. High Initial Implementation Costs
3.1.2.2. Data Privacy and Cybersecurity Concerns
3.1.3. Opportunity
3.1.3.1. Cloud-Based & Scalable Software Solutions
3.1.3.2. Partnerships & Public-Private Initiatives
3.1.4. Trends
3.1.4.1. Rise of Portable & Edge-Computing AI Devices
3.1.4.2. High Diagnostic Accuracy & Performance Gains
3.1.5. Impact Analysis
4. Industry Analysis
4.1. Porter’s Five Force Analysis – Global AI-Driven Diabetic Retinopathy Screening Market
4.2. Geopolitical & Supply Chain Exposure
4.2.1. Concentration of annotated retinal image datasets
4.2.2. Dependence on region-specific clinical validation data
4.3. Social & Patient-Centric Factors
4.3.1. Physician Acceptance & Trust in AI-Assisted DR Diagnosis
4.3.2. Human Grader Preference vs Algorithm-Based Screening
4.3.3. Patient Compliance & Screening Uptake in Asymptomatic Diabetes
4.3.4. Awareness Gaps in AI-Enabled Preventive Eye Care
4.4. Economic Factors
4.4.1. Public Health Screening Budgets & Reimbursement Structures
4.4.2. Cost Pressure on AI Development, Validation & Deployment
4.4.3. Currency & Localization Costs Impacting Global AI Vendors
4.5. Pricing Analysis
4.5.1. AI Screening Pricing Models
4.6. Regulatory Analysis
4.6.1. Regulatory Approval Pathways for AI-Based DR Screening
4.6.2. Post-Market Surveillance & Algorithm Performance Monitoring
4.6.3. Quality Management, Cybersecurity & Compliance Risks
4.6.4. Regional Regulatory Alignment & Fragmentation
4.7. Go-To-Market (GTM) Strategy
4.7.1. Deployment Across Healthcare Settings
4.8. Innovation & R&D Trends
4.8.1. Algorithm Enhancement & Multi-Disease Retinal Screening
4.8.2. Integration with Imaging Hardware & EHR Systems
4.9. Sustainability and ESG Analysis
4.9.1. Ethical AI, Data Governance & Healthcare Equity
4.10. AI-Driven DR Screening Ecosystem Participants
4.10.1. AI Software & Algorithm Developers
4.10.2. Retinal Imaging Device Manufacturers
4.10.3. Cloud Infrastructure & AI Platform Providers
4.10.4. System Integrators & Telehealth Providers
4.10.5. Public Health Agencies, NGOs & Screening Program Operators
4.11. Buyer Decision Criteria & Adoption Drivers
4.11.1. Diagnostic Accuracy & Clinical Validation
4.11.2. Regulatory Clearance & Compliance Track Record
4.11.3. Scalability, Deployment Speed & Workflow Integration
4.11.4. Cost-Effectiveness & Population-Level Screening Impact
4.12. DMI Opinion – Strategic Outlook for the Global AI-Driven Diabetic Retinopathy Screening Market
5. By Component
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
5.1.2. Market Attractiveness Index, By Component
5.2. Software
5.2.1. Image analysis & deep learning algorithms
5.2.2. Clinical decision support systems (CDSS)
5.2.3. Risk stratification & progression prediction software
5.2.4. Workflow integration & PACS connectivity
5.2.5. Data management & interoperability platforms
5.3. Hardware
5.3.1. Fundus cameras (non-mydriatic / mydriatic)
5.3.2. Portable & handheld retinal imaging devices
5.3.3. Smartphone-based retinal imaging systems
5.3.4. Edge AI processing units
5.3.5. AI-enabled OCT systems
5.4. Services
5.4.1. AI model training & validation services
5.4.2. Deployment, integration & customization services
5.4.3. Cloud hosting & data storage services
5.4.4. Regulatory compliance & clinical validation services
5.4.5. Post-deployment monitoring & technical support
6. By Screening Modality
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Screening Modality
6.1.2. Market Attractiveness Index, By Screening Modality
6.2. Automated Screening
6.2.1. Fully autonomous AI diagnostic systems
6.2.2. FDA/CE-approved autonomous detection tools
6.2.3. Population-scale screening platforms
6.3. Semi-Automated Screening
6.3.1. AI-assisted clinician review systems
6.3.2. Human-in-the-loop diagnostic platforms
6.3.3. AI-triage tools for referral prioritization
6.4. Tele-ophthalmology-Integrated Screening
6.4.1. Remote AI-based DR screening
6.4.2. Community-based mobile screening programs
6.4.3. Rural & underserved population screening
7. By Disease Severity Classification
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity Classification
7.1.2. Market Attractiveness Index, By Disease Severity Classification
7.2. No Apparent Diabetic Retinopathy
7.3. Mild Non-Proliferative Diabetic Retinopathy (NPDR)
7.4. Moderate Non-Proliferative Diabetic Retinopathy (NPDR)
7.5. Severe Non-Proliferative Diabetic Retinopathy (NPDR)
7.6. Proliferative Diabetic Retinopathy (PDR)
7.7. Diabetic Macular Edema (DME) Detection
8. By Imaging Technology
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Technology
8.1.2. Market Attractiveness Index, By Imaging Technology
8.2. Fundus Photography
8.3. Optical Coherence Tomography (OCT)
8.4. Ultra-Widefield Retinal Imaging
8.5. Fluorescein Angiography (AI-assisted analysis)
8.6. Multimodal Retinal Imaging (Fundus + OCT + Clinical Data)
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals
9.2.1. Tertiary care hospitals
9.2.2. Teaching & academic hospitals
9.3. Clinics
9.3.1. Ophthalmology clinics
9.3.2. Chain diagnostic laboratories
9.4. Ambulatory Surgical Centers (ASCs)
9.5. Primary Care Settings
9.5.1. General practitioner clinics
9.5.2. Community health centers
9.6. Others
9.6.1. Pharmacies with point-of-care screening
9.6.2. Mobile screening units
9.6.3. Government & public health programs
10. By Deployment Mode
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
10.1.2. Market Attractiveness Index, By Deployment Mode
10.2. On-Premises
10.2.1. Hospital-based AI servers
10.2.2. Edge-based AI inference systems
10.3. Cloud-Based
10.3.1. SaaS AI diagnostic platforms
10.3.2. Hybrid cloud clinical systems
10.4. Hybrid Deployment
10.4.1. Edge + cloud inference architecture
10.4.2. Offline-first AI screening solutions
11. By Clinical Workflow Integration
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Workflow Integration
11.1.2. Market Attractiveness Index, By Clinical Workflow Integration
11.2. Standalone AI Screening Tools
11.2.1. EHR-Integrated AI Systems
11.2.2. PACS-Integrated AI Platforms
11.2.3. Referral & Care Pathway Automation Systems
12. By AI Technology
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By AI Technology
12.1.2. Market Attractiveness Index, By AI Technology
12.2. Deep Learning (CNN-based models)
12.3. Machine Learning (Traditional classifiers)
12.4. Computer Vision Algorithms
12.5. Ensemble AI Models
12.6. Explainable AI (XAI) Systems
13. By Application
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.1.2. Market Attractiveness Index, By Application
13.2. Mass Population Screening
13.3. Early Disease Detection & Risk Assessment
13.4. Disease Progression Monitoring
13.5. Treatment Response Monitoring
13.6. Referral Decision Support
13.7. Clinical Research & Real-World Evidence Generation
14. By Patient Demographics
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
14.1.2. Market Attractiveness Index, By Patient Demographics
14.2. Adult Diabetic Population
14.3. Pediatric & Adolescent Diabetics
14.4. Geriatric Population
14.5. Type 1 Diabetes
14.6. Type 2 Diabetes
14.7. Gestational Diabetes (screening use cases)
15. By Regulatory & Validation Status
15.1. Introduction
15.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
15.1.2. Market Attractiveness Index, By Region
15.2. Research-Use-Only (RUO) Systems
15.3. Clinically Validated AI Tools
15.4. Regulatory-Approved Systems (FDA, CE, CDSCO)
15.5. Reimbursement-Eligible AI Solutions
16. By Region
16.1. Introduction
16.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
16.1.2. Market Attractiveness Index, By Region
16.2. North America
16.2.1. Introduction
16.2.2. Key Region-Specific Dynamics
16.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
16.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Screening Modality
16.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity Classification
16.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Technology
16.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
16.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
16.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Workflow Integration
16.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By AI Technology
16.2.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
16.2.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
16.2.13. Market Size Analysis and Y-o-Y Growth Analysis (%), By Regulatory & Validation Status
16.2.14. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
16.2.14.1. US
16.2.14.2. Canada
16.3. Europe
16.3.1. Introduction
16.3.2. Key Region-Specific Dynamics
16.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
16.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Screening Modality
16.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity Classification
16.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Technology
16.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
16.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
16.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Workflow Integration
16.3.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By AI Technology
16.3.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
16.3.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
16.3.13. Market Size Analysis and Y-o-Y Growth Analysis (%), By Regulatory & Validation Status
16.3.14. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
16.3.14.1. Germany
16.3.14.2. UK
16.3.14.3. France
16.3.14.4. Russia
16.3.14.5. Italy
16.3.14.6. Spain
16.3.14.7. Norway
16.3.14.8. Netherlands
16.3.14.9. Sweden
16.3.14.10. Denmark
16.3.14.11. Belgium
16.3.14.12. Switzerland
16.3.14.13. Austria
16.3.14.14. Poland
16.3.14.15. Finland
16.3.14.16. Rest of Europe
16.4. Latin America
16.4.1. Introduction
16.4.2. Key Region-Specific Dynamics
16.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
16.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Screening Modality
16.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity Classification
16.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Technology
16.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
16.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
16.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Workflow Integration
16.4.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By AI Technology
16.4.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
16.4.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
16.4.13. Market Size Analysis and Y-o-Y Growth Analysis (%), By Regulatory & Validation Status
16.4.14. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
16.4.14.1. Brazil
16.4.14.2. Argentina
16.4.14.3. Mexico
16.4.14.4. Chile
16.4.14.5. Colombia
16.4.14.6. Peru
16.4.14.7. Rest of Latin America
17. Asia-Pacific
17.1. Introduction
17.1.1. Key Region-Specific Dynamics
17.1.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
17.1.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Screening Modality
17.1.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity Classification
17.1.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Technology
17.1.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
17.1.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
17.1.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Workflow Integration
17.1.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By AI Technology
17.1.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
17.1.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
17.1.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Regulatory & Validation Status
17.1.13. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
17.1.13.1. China
17.1.13.2. Japan
17.1.13.3. India
17.1.13.4. South Korea
17.1.13.5. Australia
17.1.13.6. New Zealand
17.1.13.7. Singapore
17.1.13.8. Malaysia
17.1.13.9. Thailand
17.1.13.10. Indonesia
17.1.13.11. Vietnam
17.1.13.12. Philippines
17.1.13.13. Taiwan
17.1.13.14. Rest of Asia Pacific
17.2. Middle East and Africa
17.2.1. Introduction
17.2.2. Key Region-Specific Dynamics
17.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
17.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Screening Modality
17.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity Classification
17.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Technology
17.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
17.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
17.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Workflow Integration
17.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By AI Technology
17.2.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
17.2.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
17.2.13. Market Size Analysis and Y-o-Y Growth Analysis (%), By Regulatory & Validation Status
17.2.14. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
17.2.14.1. Saudi Arabia
17.2.14.2. United Arab Emirates
17.2.14.3. Qatar
17.2.14.4. Kuwait
17.2.14.5. Oman
17.2.14.6. Bahrain
17.2.14.7. South Africa
17.2.14.8. Egypt
17.2.14.9. Nigeria
17.2.14.10. Morocco
17.2.14.11. Rest of Middle East & Africa
18. Competitive Landscape Analysis
18.1. Competitive Scenario
18.2. Market Positioning/Share Analysis
18.3. Mergers and Acquisitions Analysis
18.4. Partner Identification Analysis
18.5. Investment & Funding Landscape
18.6. Strategic Alliances & Innovation Pipelines
19. Company Profiles
19.1. Digital Diagnostics lnc.
19.1.1. Company Overview
19.1.2. Product Portfolio
19.1.3. Revenue Analysis
19.1.4. Pricing Analysis
19.1.5. SWOT Analysis
19.1.6. Recent Developments
19.1.6.1. Major Deals
19.1.6.2. M&A
19.1.6.3. Collaboration
19.1.6.4. Acquisition
19.1.6.5. Joint Ventures
19.1.6.6. Innovations
19.1.7. Recent News
19.1.7.1. Events
19.1.7.2. Conferences
19.1.7.3. Symposiums
19.1.7.4. Webinars
19.2. Topcon Healthcare
19.3. Eyenuk, Inc.
19.4. AEYE Health
19.5. IRIS (Intelligent Retinal Imaging Systems).
19.6. Optomed Plc
19.7. Forus Health (3nethra)
19.8. iCare (LIST NOT EXHAUSTIVE )
20. Global AI-Driven Diabetic Retinopathy Screening Market– Research Methodology
20.1. Research Data
20.1.1. Secondary Data
20.1.2. Primary Data
20.1.3. CAGR Analysis
20.2. Market Size Estimation Methodology
20.2.1. Bottom-Up Approach
20.2.2. Top-Down Approach
20.3. Market Breakdown & Data Triangulation
20.4. Research Assumptions
20.5. Limitations
21. Appendix
21.1. About Us and Services
21.2. Contact Us